The relationship between hypomagnesemia, metformin therapy and cardiovascular disease complicating type 2 diabetes: the Fremantle Diabetes Study.

ABSTRACT:

Background

Low serum magnesium concentrations have been associated with cardiovascular disease risk and outcomes in some general population studies but there are no equivalent studies in diabetes. Metformin may have cardiovascular benefits beyond blood glucose lowering in type 2 diabetes but its association with hypomagnesemia appears paradoxical. The aim of this study was to examine relationships between metformin therapy, magnesium homoeostasis and cardiovascular disease in well-characterized type 2 patients from the community.

Methods and findings

We studied 940 non-insulin-treated patients (mean ± SD age 63.4 ± 11.6 years, 49.0% males) from the longitudinal observational Fremantle Diabetes Study Phase I (FDS1) who were followed for 12.3 ± 5.3 years. Baseline serum magnes

SUBMITTER: Peters KE 

PROVIDER: S-EPMC3760872 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature